Zealand Pharma A/S (CPH:ZEAL)
| Market Cap | 14.14B -59.9% |
| Revenue (ttm) | 4.60B -49.8% |
| Net Income | 3.09B -52.8% |
| EPS | 43.77 -52.2% |
| Shares Out | 66.84M |
| PE Ratio | 4.83 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,565 |
| Open | 211.80 |
| Previous Close | 212.70 |
| Day's Range | 210.10 - 214.70 |
| 52-Week Range | 210.10 - 556.00 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 383.58 (+81.36%) |
| Earnings Date | Nov 12, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for ZEAL stock is "Buy." The 12-month stock price target is kr 383.58, which is an increase of 81.36% from the latest price.
News
Zealand Pharma Begins Phase 2 Trial Of Petrelintide And Enicepatide For Weight Management
(RTTNews) - Zealand Pharma A/S (ZEAL.CO) announced the start of the Phase 2 ZYNERGY trial evaluating petrelintide in combination with enicepatide in people with obesity or overweight and at least one ...
Zealand Pharma initiates ZYNERGY trial
Zealand Pharma (ZLDPF) announced initiation of ZYNERGY, a Phase 2 dose-finding trial in participants with obesity or overweight with at least one weight-related comorbidity. The trial compares once-we...
Zealand Pharma Transcript: Jefferies Global Healthcare Conference
Progress spans late-stage obesity and rare-disease assets, research partnerships and a goal of 10 new metabolic-health clinical programs. Management emphasized petrelintide’s tolerability, survodutide’s liver-fat profile and faster, AI-enabled research.
Zealand Pharma Wins EU Approval For Zeydovio To Treat Short Bowel Syndrome
(RTTNews) - Zealand Pharma A/S (ZLDPF.PK, ZEAL.CO), a biotechnology company focused on metabolic health, announced Friday that the European Commission has granted marketing authorization for Zeydovio ...
Zealand Pharma announces EU approval of Zeydovio for SBS
Zealand Pharma (ZLDPF) announces that the European Commission has granted marketing authorization for Zeydovio, a long-acting, next-generation GLP-2 analog, for the treatment of adults with short bowe...
Zealand Pharma Earnings Call Transcript: Q3 2026
9M revenue reached DKK 4.5bn and profit DKK 3.5bn, with DKK 13.5bn cash at September-end. Petrelintide advanced into phase III, survodutide completed its obesity phase III program, and FY expense guidance narrowed.
Zealand Pharma Quarterly report: Q3 2026
Zealand Pharma has published its Q3 2026 quarterly earnings report on November 12, 2026.
Zealand Pharma Slides: Q3 2026
Zealand Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 12, 2026.
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Misses Revenue Estimates
Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +90.98% and -97.57%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stoc...
Boehringer, Zealand's obesity drug did not raise heart risks in trial, data shows
Zealand Pharma and Boehringer Ingelheim's experimental obesity drug did not increase the risk of serious heart problems compared to a placebo in a late-stage trial, the companies said on Monday.
Zealand Pharma says Boehringer Ingelheim Phase 3 trial met primary endpoint
Zealand Pharma (ZLDPF) announced that Boehringer Ingelheim has reported results from the Phase 3 SYNCHRONIZE-CVOT trial, the first and only global cardiovascular safety trial of a glucagon/GLP-1 dual ...
Zealand Pharma's ZP9830 Shows Favorable Tolerability In Phase 1 Trial
(RTTNews) - Monday, Zealand Pharma A/S (ZEAL.CO) announced positive topline results from the multiple ascending dose (MAD) portion of its Phase 1 trial evaluating ZP9830, an investigational Kv1.3 ion ...
Zealand Pharma announces results from ZP9830 trial
Zealand Pharma (ZLDPF) announced Phase 1 multiple ascending dose, or MAD, topline results for the company’s Kv1.3 ion channel blocker, ZP9830. The MAD part of the first-in-human, single-center, random...
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
Generate Biomedicines (GENB) announced a multi-target strategic collaboration with Zealand Pharma (ZLDPF). Under the collaboration, the companies intend to design and develop multispecific protein the...
Zealand Pharma opens research hub in Cambridge, Massachusetts
Zealand Pharma (ZLDPF) celebrated the opening of its new research hub at 35 CambridgePark Drive in Cambridge, Massachusetts, with a ribbon-cutting ceremony. The site, first announced in March 2026, is...
Zealand Pharma slides as concerns over patients quitting survodutide trials resurface
Nearly one in five patients quit Zealand Pharma's late-stage survodutide trial due to gastrointestinal side effects caused by the obesity drug, data released on Thursday showed, again raising invest...
Zealand announces initiation of registrational Phase 3 ZUPREME program
Zealand Pharma (ZLDPF) announces the initiation of the global registrational Phase 3 ZUPREME program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overw...
Zealand Pharma's short bowel syndrome drug wins backing from EU panel
Zealand Pharma received a positive opinion from the Committee for Medicinal Products for Human Use recommending approval of its drug candidate Zeydovio for the treatment of short bowel syndrome, the...
Zealand Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted ambitious growth plans in metabolic health, with a focus on launching petrelintide and advancing combination therapies for obesity, supported by strong partnerships with Roche and Boehringer. Key rare disease assets and an expanding early-stage pipeline underscore a strategy centered on innovation, patient-centricity, and upcoming pivotal data and regulatory milestones.
Elvinix announces exclusive license agreement with Zealand Pharma
Elvinix announced an exclusive license agreement with Zealand Pharma (ZLDPF), granting Elvinix the rights to develop and commercialize Zealand’s GLP-1/gastrin dual-agonist peptide portfolio. Under the...
Zealand Pharma downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Zealand Pharma (ZLDPF) to Equal Weight from Overweight with a price target of DKK 330, down from DKK 425. The company has a “lean slate” of potential catalysts…
Zealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorgan
JPMorgan lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 435 from DKK 460 and keeps an Overweight rating on the shares.
Zealand Pharma enters $100M royalty purchase, sale pact with Royalty Pharma
Zealand Pharma (ZLDPF) announced that it has entered into a royalty purchase and sale agreement with Royalty Pharma (RPRX) in exchange for Zealand Pharma’s economics related to rusfertide, a potential...
Zealand Pharma price target raised to DKK 420 from DKK 410 at Wells Fargo
Wells Fargo raised the firm’s price target on Zealand Pharma (ZLDPF) to DKK 420 from DKK 410 and keeps an Overweight rating on the shares. The company reported inline Q2…
Zealand Pharma Earnings Call Transcript: Q2 2026
Strong H1 2026 performance with double-digit weight loss from petrelintide, robust cash position, and key pipeline advances. Survodutide phase III trials met endpoints, and $100M royalty monetization boosts capital for strategic growth.